Stride, Inc. LRN gained 17.9% since it released its second-quarter fiscal 2025 results on Jan. 28, 2025. The stock’s strong ...

Rapt Therapeutics (RAPT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...